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CASE REPORT Open Access
A germline mutation of CDKN2A and a
novel RPLP1-C19MC fusion detected in a
rare melanotic neuroectodermal tumor of
infancy: a case report
David J. Barnes1, Edward Hookway1, Nick Athanasou1, Takeshi Kashima1ˆ, Udo Oppermann1, Simon Hughes2,
Daniel Swan2, Dietrich Lueerssen2, John Anson2 and A. Bassim Hassan1,3*
Abstract
Background: Melanotic neuroectodermal tumor of infancy (MNTI) is exceptionally rare and occurs predominantly
in the head and neck (92.8 % cases). The patient reported here is only the eighth case of MNTI presenting in an
extremity, and the first reported in the fibula.
Case presentation: A 2-month-old female presented with a mass arising in the fibula. Exhaustive genomic,
transcriptomic, epigenetic and pathological characterization was performed on the excised primary tumor and a
derived cell line. Whole-exome analysis of genomic DNA from both the tumor and blood indicated no somatic,
non-synonymous coding mutations within the tumor, but a heterozygous, unique germline, loss of function
mutation in CDKN2A (p16INK4A, D74A). SNP-array CGH on DNA samples revealed the tumor to be euploid, with no
detectable gene copy number variants. Multiple chromosomal translocations were identified by RNA-Seq, and
fusion genes included RPLP1-C19MC, potentially deregulating the C19MC cluster, an imprinted locus containing
microRNA genes reactivated by gene fusion in embryonal tumors with multilayered rosettes. Since the presumed
cell of origin of MNTI is from the neural crest, we also compared gene expression with a dataset from human
neural crest cells and identified 185 genes with significantly different expression. Consistent with the melanotic
phenotype of the tumor, elevated expression of tyrosinase was observed. Other highly expressed genes encoded
muscle proteins and modulators of the extracellular matrix. A derived MNTI cell line was sensitive to inhibitors of
lysine demethylase, but not to compounds targeting other epigenetic regulators.
Conclusions: In the absence of somatic copy number variations or mutations, the fully transformed phenotype of
the MNTI may have arisen in infancy because of the combined effects of a germline CDKN2A mutation, tumor
promoting somatic fusion genes and epigenetic deregulation. Very little is known about the etiology of MNTI and
this report advances knowledge of these rare tumors by providing the first comprehensive genomic, transcriptomic
and epigenetic characterization of a case.
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Background
Melanotic neuroectodermal tumor of infancy (MNTI) pre-
sents as a painless, pigmented, rapidly expansile and lobu-
lated lesion that primarily affects infants in their first year
of life, with 80 % of patients being less than 6-months-old
(extensively reviewed by Kruse-Lösler in 2006) [1]. Up to
92.8 % cases of MNTI affect the head and neck, mostly the
maxilla (68–80 %), skull (10.8 %), mandible (6 %) and brain
(4.3 %) [1]. There is a slight trend towards a greater inci-
dence in males than females (ratio = 1.48) [1]. MNTI is gen-
erally considered to be benign, although the tumors grow
rapidly, can be invasive and metastasize in 6.5 % of cases
[2]. The treatment of choice for MNTI is radical surgery
and a curative outcome is achieved in the majority of cases
[2, 3]. Where surgery might be mutilating, chemotherapy
has occasionally been successful, but it is generally consid-
ered that chemotherapy and radiotherapy are ineffective
in controlling this disease [1, 4]. Post-operative recurrence
rates for MNTI range from 10 to 60 % [3]. Late-returning
disease following resection is rare, however, 39.3 % of all
cases develop recurrence within 4 weeks of surgery and
up to 71.4 % of cases recur within 4 months [1].
Microscopically, MNTI is described as a biphasic
tumor consisting of small, round ‘neuroblast’-like cells
with scant cytoplasm and larger, melanin-expressing,
polygonal, ‘epithelial’-like cells in a desmoplastic stroma
[5–7]. It is unclear which of these cell populations repre-
sent the main proliferative component of the tumor.
Whereas immunohistochemistry indicates that expres-
sion of cell cycle proteins is restricted to the melanocytic
cells [8], in cases where the MNTI has exhibited malig-
nant behavior and metastasis, the dominant cell type has
appeared neuroblastic [5, 6]. A neural crest origin for
MNTI was proposed independently by Misugi et al. [9],
on the basis of electron microscopic examination of a
tumor, and Borello and Gorlin [10] who also observed that
the high urinary levels of vanillylmandelic acid, the main
end-stage metabolite of catecholamines, returned to nor-
mal in a patient after the tumor had been excised. Subse-
quent electron microscopy studies [7] have identified
ultra-structural features, including characteristic melanin
granules and modified tight-junctions that support the
view that MNTI is derived from the neural crest. We con-
sider this report to be of interest as it is, to the best of our
knowledge, the first comprehensive genomic and tran-
scriptomic characterization of an MNTI. The patient re-
ported here is only the eighth case of MNTI presenting in
an extremity, and the first reported in the fibula.
Case presentation
A 2-month old female was referred to the Nuffield
Orthopaedic Centre (Oxford) after her parents noticed a
swelling on her left lower leg. A pigmented tumor measur-
ing 5 × 2.5 × 2.5 cm was excised with wide margins. Upon
histological examination, clumps and cords of tumor cells
with scanty cytoplasm and large hyperchromatic or ves-
icular nuclei were observed. Some of the tumor cells also
contained pigment of melanin (Fig. 1a, b, c). Immunohis-
tochemistry showed that the tumor cells expressed vimen-
tin, CD99 (Fig. 1d), HMB45 (Fig. 1e), NSE and cytokeratin
(CK7+, CK20-). Nuclei stained for BAF47 and a high frac-
tion of cells were proliferative identified with Ki-67. Some
of the stromal cells stained for epithelial membrane anti-
gen. There was also stromal staining for smooth muscle
antigen and muscle actin. There was no specific staining
for GFAP, myogenin, CD68, melan A, chromogranin,
FABP4/aP2, CD117, podoplanin, alpha-fetoprotein, HCG,
CD34, caldesmon, CD3, S100, CD45, desmin, CD20 and
CD31. The tumor was present within the bone medulla
and had spread through the cortex into covering muscle,
fat and fibrous tissue. There were focal areas of tumor ne-
crosis. Morphological features and immunohistochemistry
were consistent with an MNTI. The patient is the subject
of follow-up, and 3 years after surgery remains well with
no recurrence.
We derived a cell line from the tumor that at low pas-
sage (<5) consisted of two distinct populations of adherent
cells, one of which was highly melanotic (Fig. 1f). After 5
passages in culture, the densely pigmented cells were no
longer apparent, and the culture consisted of fibroblasts
which no longer produced melanin (Fig. 1g). Immunohis-
tochemical analysis of the cells at passage 6, however, re-
vealed a profile in keeping with the surgical resection
specimen with strong staining for NSE and HMB45.
Characterization of the MNTI genome
As many pediatric small round cell tumors have either
amplification of chromosomal regions containing proto-
Barnes et al. BMC Cancer  (2016) 16:629 Page 2 of 14
oncogenes or deletion of regions containing tumor sup-
pressor genes, our expectation was that the MNTI would
have copy number variations (CNV). By hybridizing gen-
omic DNA from the MNTI and from the patient’s blood
(the reference signal) to a human whole-genome SNP
array (4 × 180 k design with a greater density of probes
covering 1500 cancer-associated genes), the CNV data
proved to be featureless (Fig. 2, innermost track), indicat-
ing that the MNTI was predominantly euploid.
Whole-exome sequencing on genomic DNA from both
the MNTI and from the patient’s blood, aimed to identify
somatic variants by subtracting the germline variants from
the total variants detected in the MNTI. All of the somatic
single nucleotide variants (SNVs) found in the tumor were
synonymous. The patient had eight germline SNVs, which
were predicted to be deleterious by any or all of the SIFT,
PolyPhen or Condel algorithms (www.ensembl.org/info/
docs/tools/vep/index.html), and four germline indels. All
but one of the indels had prior annotation in dbSNP, and
seven of the SNVs may be regarded as SNPs because they
were annotated as such in either dbSNP or HGMD. Of
most interest, was the SNV in exon 2 of CDKN2A
(Chromosome 9:21971137, T to G) which causes mutation
of aspartic acid to alanine at position 74 in p16INK4A and
is listed in COSMIC (COSM4163712) as a rare somatic
mutation (Table 1). This variant is not a known founder
mutation and, until now, has never been described in the
germline. In the alternate reading frame of CDKN2A, the
corresponding variant is synonymous causing a silent
R88R mutation in p14ARF. No parental DNA was available
to identify whether the CDKN2A (p16INK4A, D74A) muta-
tion was a new mutation or inherited.
Characterization of the MNTI transcriptome and detection
of fusion genes
By RNA-Seq, we wished to identify differentially
expressed genes and fusion genes that might be relevant
as potential drivers of the tumorigenesis. As the tumor
had been frozen, we were able to extract high quality
RNA that was subjected to ultra-high depth (>200 mil-
lion reads), paired-end RNA sequencing. Analysis with
FusionCatcher [11] yielded 50 candidate fusion genes
(Table 2 and Additional file 1: Table S1), indicating that
the tumor had genomic instability. Intra-chromosomal
events were required for 29 of the fusion genes and 23
of these were predicted to be read-through transcripts.
Chromosomal translocations were involved in the forma-
tion of the remaining 21 fusion genes and for three of these
(H2AFV-RP11-386 M24.4, C19MC-RPLP1 and RBBP4-
TRA@) reciprocal fusions were identified suggesting
Fig. 1 Pathological characterization of the MNTI tumor. The two main tumor cell types are readily apparent following haematoxylin and eosin-stained
section from the tumor: (a) nests of small round cells with scant cytoplasm and hyperchromatic nuclei (top) and cords of polygonal, ‘epithelial-like’ cells
containing speckles of melanin (bottom center), (b) Scattered pigment-containing tumor cells in bone, (c) MNTI tumor cells in soft tissue with residual
muscle fibers evident. Tumor cells stain positive for CD99 (d) and HMB45 (e). f Bright field images of the cell line derived from the MNTI at passage 2
produced copious amounts of melanin causing cell clumps to appear black. g Phase contrast image of passage 6 of the cell line no longer synthesized
melanin and the cells had adopted a more fibroblast-like morphology but remain positive for HMB45 (h) and NSE (i). Scale bars = 50 μm
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balanced translocation had occurred. The fusion of RPLP1,
which encodes the large P1 ribosomal protein, to C19MC,
the largest microRNA cluster in the human genome, lo-
cated on chromosome 19q13.41, appears potentially func-
tional. The ~100 kb cluster of 46 microRNA genes is
imprinted, with expression largely confined to the first tri-
mester of gestation [12]. Four collagen genes (COL1A1,
COL1A2, COL3A1 and COL18A1) were also re-arranged
by chromosomal translocation in the MNTI, with COL1A1
and COL3A1 having multiple fusion partners (Fig. 2).
Since the presumed cell of origin of MNTI is from the
human neural crest (7,9,10), we also asked how the tran-
scriptional profile of our patient’s tumor might differ from
that of human neural crest cells (hNCC). Rada-Iglesias et
Fig. 2 Genomic status of MNTI primary tumor. Circos plot of genomics data. Innermost track: Scatterplot of log2 (signal intensity ratios) for SNP
array probes. Genomic DNA from the patient’s tumor and blood (reference signal) were hybridized to a custom 4 x 180 k SNP array containing
probes for the whole-genome with a greater density for 1500 cancer-associated genes. There were no apparent copy number variations and the
tumor was euploid. Blue and beige shaded sections represent ranges over which genomic losses or gains, respectively, would be expected to
occur. Bar graph track: 185 genes are significantly (adjusted P-value≤ 0.05) up-regulated (red) or down-regulated (blue) in the MNTI relative to
their expression in an RNA-Seq dataset (GEO accession: GSE28875) for in vitro-differentiated human neural crest cells (hNCC). Bars represent log2
(FPKM + 0.01) fold-changes. Links: thin gray links are shown between partner genes for fusions where the reciprocal has not been detected,
except for COL3A1 and COL1A1, where rearrangements with multiple partner genes are predicted by the FusionCatcher analysis. Thicker links are
shown for fusion genes where the reciprocal has been detected: RPLP1-C19MC (magenta), H2AFV-RP11-386 M24.4 (purple) and RBBP4-TRA@ (green)
Table 1 Germline variants in the MNTI
Gene Variant
type
Chr Position Ref/Seq Amino acid Transcript Read
depth
Existing annotation
(Allelic frequency)
Sift Polyphen Condel
CDKN2A SNV 9 21970916 C/T Ala/Thr ENST00000304494.9 322 CM004869 (0.027) deleterious benign neutral
CDKN2A SNV 9 21971137 T/G Asp/Ala ENST00000304494.9 105 COSM4163712 (NA) deleterious probably_
damaging
deleterious
CHD1 Indel 5 98192165 AGG/– Pro/Unknown ENST00000284049.7 NA NA NA NA NA
No tumor-specific non-synonymous mutations were identified and these variants were also detected in germline DNA extracted from the patient’s blood. A
heterozygous T/G mutation on chr 9:21971137 generates a mutant allele of CDKN2A which encodes a p16INK4A protein with substitution of aspartic acid for
alanine at position 74. This change is predicted to be damaging or deleterious by the Sift, Polyphen and Condel algorithms and mutations of Asp74 in CDKN2A
are documented in COSMIC as rare tumor variants. The other CDKNA mutation (Ala/Thr) is not predicted to be damaging to the function of p16INK4A. Common
polymorphisms with a dbSNP annotation have been excluded
SNV single nucleotide variant, NA = not available
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Table 2 Fusion genes (50) detected in the MNTI by FusionCatcher analysis of RNA-Seq data
Fusion gene Location of 5’ partner Location of 3’ partner Cause of fusion
RPLP1-C19MC 15:69745292:+ 19:54278860:+ Balanced chromosomal translocation
C19MC-RPLP1 19:54278886:+ 15:69745266:+ Balanced chromosomal translocation (reciprocal fusion)
RP11-386 M24.4-H2AFV 15:93276847:- 7:44873962:- Balanced chromosomal translocation
H2AFV-RP11-386 M24.4 7:44875191:- 15:93277223:- Balanced chromosomal translocation (reciprocal fusion)
TRA@-RBBP4 14:22032433:+ 1:33133924:+ Balanced chromosomal translocation
RBBP4-TRA@ 1:33146113:+ 14:22034317:+ Balanced chromosomal translocation (reciprocal fusion)
COL1A1-DES 17:48261671:- 2:220290692:+ Chromosomal translocation
COL1A1-SCARB2 17:48262192:- 4:77109675:- Chromosomal translocation
COL1A1-PLTP 17:48264070:- 20:44537829:- Chromosomal translocation
COL1A1-TRIOBP 17:48264212:- 22:38126504:+ Chromosomal translocation
COL3A1-COL18A1 2:189851865:+ 21:46925141:+ Chromosomal translocation
COL3A1-FAT1 2:189871155:+ 4:187561585:- Chromosomal translocation
COL3A1-CD81 2:189871176:+ 11:2411930:+ Chromosomal translocation
COL3A1-ATP5B 2:189873714:+ 12:57037364:- Chromosomal translocation
COL3A1-LRP1 2:189876968:+ 12:57597641:+ Chromosomal translocation
CTSB-COL3A1 8:11703238:- 2:189873743:+ Chromosomal translocation
DDOST-ELMOD1 1:20978357:- 11:107525369:+ Chromosomal translocation
EEF2-TAGLN2 19:3982389:- 1:159888278:- Chromosomal translocation
IGK@-LL22NC03-2H8.5 2:90296180:+ 22:22640524:- Chromosomal translocation
PINK1-AS-ELMOD1 1:20978357:- 11:107525369:+ Chromosomal translocation
PPP2R5C-RP11-168 J18.6 14:102375968:+ 3:52408668:+ Chromosomal translocation
SERPINF1-SPARC 17:1680627:+ 5:151044730:- Chromosomal translocation
TAF1C-COL1A1 16:84218540:- 17:48268811:- Chromosomal translocation
TSIX-COL1A2 X:73020413:+ 7:94060360:+ Chromosomal translocation
COL3A1-CHPF 2:189860508:+ 2:220404337:- Intra-chromosomal deletion
FBXL18-TNRC18 7:5530862:- 7:5434226:- Intra-chromosomal deletion
LSP1-TNNT3 11:1908806:+ 11:1944087:+ Intra-chromosomal deletion
SMC5-AS1-MAMDC2-AS1 9:72831202:- 9:72703410:- Intra-chromosomal deletion
TFDP2-XRN1 3:141820577:- 3:142084208:- Intra-chromosomal deletion
TPST1-GS1-124 K5.4 7:65751696:+ 7:65960242:+ Intra-chromosomal deletion
ARMC9-AC017104.6 2:232234836:+ 2:232258192:+ Read-through transcript
BCKDK-KAT8 16:31123348:+ 16:31128784:+ Read-through transcript
C17ORF107-GP1BA 17:4902763:+ 17:4934342:+ Read-through transcript
C1GALT1-AC005532.5 7:7283381:+ 7:7317216:+ Read-through transcript
CD4-P3H3 12:6925379:+ 12:6938651:+ Read-through transcript
CHD4-NOP2 12:6680035:- 12:6677088:- Read-through transcript
EIF3K-ACTN4 19:39116742:+ 19:39191240:+ Read-through transcript
FAM89B-EHBP1L1 11:65341233:+ 11:65346549:+ Read-through transcript
GPR141-NME8 7:37725186:+ 7:37896876:+ Read-through transcript
GPX7-FAM159A 1:53072617:+ 1:53108535:+ Read-through transcript
HEPHL1-PANX1 11:93800909:+ 11:93862494:+ Read-through transcript
LMO1-RIC3 11:8248522:- 11:8174970:- Read-through transcript
LMO7-AS1-COMMD6 13:76209965:- 13:76123565:- Read-through transcript
NPTXR-DNAL4 22:39219088:- 22:39177014:- Read-through transcript
Barnes et al. BMC Cancer  (2016) 16:629 Page 5 of 14
al. [13] developed an in vitro model which recapitulates
neural crest formation during gestation by inducing differ-
entiation of human embryonic stem cells, first into neu-
roectodermal spheres, and then into migratory hNCC. We
compared our RNA-Seq expression data from the tumor
with the single RNA-Seq dataset obtained from the differ-
entiated hNCC (GEO acession: GSE28875). The transcrip-
tional profiles were highly similar, in keeping with an
hNCC origin for MNTI, with no significant differences in
expression for 24146 transcripts out of 24331. We identi-
fied just 185 genes with expression that was significantly
different (adjusted P-value ≤ 0.05, Fig. 2, bar graph track).
The 25 genes showing the greatest differences in expres-
sion (Table 3) encode proteins with diverse functions in-
cluding: ribosomal proteins (RPS17), serum transport
proteins (TTR), transcription factors (POU3F3, TFAP2B,
SP8) and extracellular matrix proteins (SPON2, DPT).
Amongst them is a subgroup of genes that encode compo-
nents of muscle (TNNT3, MYL1, MYL2, TNNI2), consist-
ent with the finding of strong staining of stromal cells for
smooth muscle actin and muscle actin, suggesting that the
MNTI has undergone myogenic differentiation. Of note,
TYR, which encodes tyrosinase, the enzyme that catalyzes
the initial steps in the biosynthesis of melanin from tyro-
sine, was highly expressed in the MNTI, in keeping with
its melanotic phenotype, but was not expressed in hNCC.
The microRNA (miR) gene MIR4737, was the most
highly expressed gene in hNCC relative to the MNTI, in
which it was not expressed. Down-regulation of expres-
sion of MIR4737 in the MNTI implies that the target
genes for this miR will be up-regulated. From TargetScan
(www.targetscan.org), we identified 465 potential targets
of hsa-miR-4737, of which only two, EDN2 and MYOD1,
were significantly upregulated in the MNTI. The loss of
repression of MYOD1, is also consistent with myogenic
differentiation and the expression of muscle component
genes in the MNTI.
In order to gain insight into how genes differentially
expressed in the MNTI, relative to hNCC, might be
functioning in a coordinated manner, we carried out a
gene set enrichment analysis (GSEA). A total of 28 gene
sets were upregulated in the MNTI (data not shown), of
which the set having the highest normalized enrichment
score was from genes that are enriched in invasive ductal
breast carcinoma [14]. The leading edge set of genes
from the MNTI enriched in this set comprised: THBS2,
SPON2, HLA-DRA, LRRC15, TYROBP, MMP13, LY96,
C1QB and C1QA. The coordinated expression of these
genes is suggestive of an epithelial to mesenchymal tran-
sition (EMT) mediated by the transcriptional regulator
Twist1 [14], even though TWIST1 expression was not
significantly different in the MNTI from its expression
in hNCC.
Sensitivity of a cell line derived from the MNTI to
inhibitors of Cdk4/Cdk6 and lysine demethylase
We reasoned that the potential loss of regulation of
Cdk4/Cdk6 due to mutation of an allele of CDKN2A
would be expected to make cells of the MNTI more sus-
ceptible to cytotoxicity induced by Cdk4/Cdk6 inhib-
ition. To test this, we treated the cell line derived from
the MNTI with palbociclib, a specific small molecule in-
hibitor of Cdk4/Cdk6 [15]. For comparison, we also
treated Ewing sarcoma cell lines with palbociclib that
were wild-type (SK-N-MC) or had hemizygous deletion
(CHP-100) or were nullizygous (A673) for CDKN2A,
confirmed by SNP arrayCGH in our laboratory (results
not shown). Although not statistically significant, differ-
ences in sensitivity were observed (Fig. 3f ), with the
MNTI cells proving to be the most sensitive to palboci-
clib (mean IC50 ± s.d., 6.01 ± 2.01 μM) and Ewing cell
lines with CDKN2A deletions (CHP-100 and A673) be-
ing the least sensitive (mean IC50 ± s.d., 8.03 ± 0.84 and
7.92 ± 1.27 μM, respectively; MNTI IC50 vs. CHP-100
IC50, P = 0.4, Mann–Whitney test).
Since we had been unable to detect any unequivocal
driver mutations, previously described oncogenic fusion
genes or CNV that might account for tumorigenesis of
Table 2 Fusion genes (50) detected in the MNTI by FusionCatcher analysis of RNA-Seq data (Continued)
RFPL1-NEFH 22:29838118:+ 22:29876241:+ Read-through transcript
SIX3-AC012354.6 2:45171866:+ 2:45193557:+ Read-through transcript
SLC25A43-SLC25A5 X:118544325:+ X:118602415:+ Read-through transcript
SSSCA1-EHBP1L1 11:65341233:+ 11:65346549:+ Read-through transcript
TBC1D23-NIT2 3:100039815:+ 3:100057931:+ Read-through transcript
TMEM101-PYY 17:42100940:- 17:42043900:- Read-through transcript
VPS45-PLEKHO1 1:150082742:+ 1:150123102:+ Read-through transcript
ZCWPW2-LINC00693 3:28562607:+ 3:28616561:+ Read-through transcript
ZNF836-ZNF616 19:52663718:- 19:52633841:- Read-through transcript
Location of fusion points is given as: chromosome : genomic coordinates : strand. Where FusionCatcher has returned multiple fusion point coordinates, the
location with the most unique spanning reads is listed. Reciprocal fusions, indicative of balanced chromosomal translocations, were detected for three fusion
genes (C19MC-RPLP1, H2AFV-RP11-386 M24 and RBBP4-TRA@). Two fusion genes reported by FusionCatcher as being ‘probable false positives’ have been excluded
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the MNTI, we hypothesized that epigenetic mechanisms
might be involved. Furthermore, we observed variegation
upon deriving the MNTI cell line, with a population of
differentiated, melanotic cells co-existing with a less
differentiated population at early passages (Fig. 1f ). The
differentiated cells did not persist into later passages
(Fig. 1g), which suggested a phenotypic switch. Accord-
ingly, we tested a selection of 47 small molecule inhibi-
tors targeted against a broad range of proteins involved
in epigenetic processes to investigate the importance of
epigenetic alterations on the viability and phenotype of
the MNTI cell line in culture (Fig. 3). Our rationale for
testing this panel was that it would permit candidate en-
zymes to be identified that were either required for
maintaining growth of the tumor or that were respon-
sible for the phenotypic switch to a less differentiated
state. Viability was reduced when cells were treated with
compounds targeting lysine demethylase enzymes
(Fig. 3d). Enzymes affected included: the 2-oxygluterate
(2-OG) oxygenase family, inhibited by IOX1, the Jumonji
C (JmjC) domain-containing superfamily, inhibited by
JIB-04 and Methylstat, and JARID1B/KDM5B, UTX/
KDM6A and lysine demethylase 6B, which were all tar-
gets of GSK-J4. GSK-J5, a less active isomer of GSK-J4
had little effect. In contrast, bromodomain inhibitors
(Fig. 3a), histone deacetylase inhibitors (Fig. 3b) and
methyltransferase inhibitors (Fig. 3c) did not cause cell
death, with the exception of chaetocin, which also in-
hibits thioredoxin reductase [16]. The sensitivity of the
MNTI cell line to compounds targeting different classes
of epigenetic regulators (Fig. 3e), though variable, was
less than for inhibitors of lysine demethylase enzymes.
Although none of these results achieved statistical
significance (pairwise Wilcoxon rank sum tests with
Holm correction, all P > 0.05) they do point to a
trend. Overall, our data suggest that epigenetic mech-
anisms and, in particular, the balance between methy-
lation and demethylation of histone lysines are
required for maintaining the viability of tumor cells
in the MNTI.
Table 3 The 25 most differentially expressed genes in the MNTI relative to the hNCC dataset
Gene Description Chromosome Expression (FPKM)
MNTI hNCC
RPS17 Ribosomal protein S17 15 1616.3 0.0
TTR Transthyretin 18 532.5 2.6
THBS2 Thrombospondin 2 6 298.3 0.5
TNNT3 Troponin T type 3 (skeletal, fast) 11 266.4 0.0
BPIFB4 BPI fold containing family B, member 4 20 262.5 0.0
TMEM176A Transmembrane protein 176A 7 172.9 0.0
SPON2 Spondin 2, extracellular matrix protein 4 169.2 2.0
HLA-DRA Major histocompatibility complex, class II, DR alpha 6 162.7 0.0
TYR Tyrosinase 11 144.2 0.0
MYL1 Myosin, light chain 1, alkali; skeletal, fast 2 141.2 0.0
FDCSP Follicular dendritic cell secreted protein 4 117.7 0.0
MYL2 Myosin, light chain 2, regulatory, cardiac, slow 12 117.4 0.0
LRRC15 Leucine rich repeat containing 15 3 105.6 0.0
IL32 Interleukin 32 16 105.6 0.0
DPT Dermatopontin 1 99.9 0.0
LYPD2 LY6/PLAUR domain containing 2 8 73.3 0.0
TNNI2 Troponin I type 2 (skeletal, fast) 11 71.2 0.0
MEG3 Maternally expressed 3 (non-protein coding) 14 57.9 0.6
MIR770 microRNA 770 14 57.9 0.6
MT1E Metallothionein 1E 16 46.2 0.0
TYROBP TYRO protein tyrosine kinase binding protein 19 43.2 0.0
SLC1A7 Solute carrier family 1 (glutamate transporter), member 7 1 42.5 0.0
POU3F3 POU class 3 homeobox 3 2 0.0 54.3
MTRNR2L10 MT-RNR2-like 10 X 0.0 89.6
MIR4737 microRNA 4737 17 0.0 1873.8
FPKM fragments per kilobase per million mapped reads, hNCC human neural crest cells
Barnes et al. BMC Cancer  (2016) 16:629 Page 7 of 14
Fig. 3 Responses of MNTI cell line to epigenetic inhibition and a CDK4/CDK6 inhibitor. MNTI cells were treated with bromodomain inhibitors (a),
histone deacetylase inhibitors (b), histone methyltransferase inhibitors (c), lysine demethylase inhibitors (d) or miscellaneous inhibitors (e). Cell
viability was reduced in response to a range of small molecule inhibitors of lysine demethylases (d) but was unaffected by inhibitors of other
epigenetic mechanisms. Results are normalized to the vehicle control and represent the mean ± s.d. of either 3 biological replicates (day 3, mid
gray) or 2 biological replicates (days 7, light gray and 10, dark gray). f Log dose–response curves for CD4/CDK6 inhibitor palbociclib-treated MNTI
cells ( , magenta) and Ewing sarcoma cell lines: CHP-100 ( , purple), A673 ( , teal) and SK-N-MC ( , orange). Cells were treated with doses
of palbociclib or vehicle control (DMSO) for 72 h and those remaining viable were assayed using the MTS reagent. Percentage of viable cells was
calculated by normalizing absorbance readings taken at 490 nm. Data are mean ± s.e.m. and representative curves from one of three independent
experiments are shown. Inhibitors in (e) targeted: kinases (K00135, 5-iodotubercidin), a methyl-lysine reader (UNC1215), PARP (rucaparabib, olaparib),
PHD2 (IOX2), tRNA synthetase (MAZ1392, MAZ1805), DNA methyltransferase (5-aza-deoxy-cytidine, 5-azacitidine) and arginine deiminase (GSK484 low
and high doses shown)
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Conclusions
Presentation of MNTI in the extremities is rare, with
only 7 previous cases having been reported, and so this
case may not be representative of all reported cases. In 6
cases the lower limb was affected, with the tumor origin-
ating in the femur [4, 17–19] or in soft tissues [20, 21].
There is a single report of a case of MNTI in the upper
limb [22]. Femoral MNTIs appear to exhibit malignant
features and had a poor clinical outcome. In the case de-
scribed by Johnson et al. in 1983, an 18-month-old girl
had an aggressive MNTI in her left femur which metas-
tasized to the pelvis within 2 months [4]. In the cases
reported by Elli et al. [17] and Choi et al. [18], the tu-
mors were both large and surgery was considered too
mutilating. The first patient, a 3-month-old female in-
fant, was lost to follow-up after the parents refused
chemotherapy [17], while the second, a 5-month-old
male, died of heart failure owing to the cardiotoxicity of
the chemotherapy [18]. The femoral MNTI reported by
Rekhi et al. was also large but was successfully resected
and the patient, a 12-month-old male, was the subject of
follow-up at the time of publication [19].
Despite such case reports, attempts at unbiased gen-
etic characterization of MNTI tumors have not been re-
ported. We exploited massively parallel next generation
sequencing technologies to perform an exhaustive mo-
lecular genomic and transcriptomic survey of an MNTI.
Whole-genome array-CGH data revealed the patient’s
tumor to be euploid, suggesting that CNV are less likely
to be involved in the etiology of MNTI in this case. We
detected a heterozygous mutated CDKN2A (p16INK4A,
D74A) allele, but not LOH of CDKN2A and transcripts
from both alleles were expressed at levels comparable to
those in hNCC, indicating the mutation may exhibit
haploinsufficiency (data not shown). The absence of
CNV is perhaps not surprising, given that they appear to
occur less frequently in other small round cell tumors in
childhood. Moreover, karyotypic analysis by Khoddami
et al. [23] tested three MNTI for molecular lesions
associated with other pediatric small cell tumors: MYC
amplification, deletion of 1p (both of which are features
of neuroblastoma), and chromosomal translocations
(t(11;22)(q24;q12), t(11;22)(p13;q12), responsible for
Ewing sarcoma and desmoplastic small round cell tumor,
respectively. None of these abnormalities were detected.
Few cell lines have been derived from MNTI, of which
the best characterized histologically and cytogenetically
are the 3 MNTI lines described by Metwaly et al. [24].
These lines were hypotriploid, with a modal chromo-
some number of 65, and had multiple chromosomal
abnormalities and CNV [24]. It is possible that the
MNTI lines were heterogeneous, as the karyotypes and
chromosomal abnormalities differed in the 3 clones des-
pite being derived from the same original maxillary
tumor. Although we did not specifically test ploidy in
the derived cell line, our data suggest that either CNV
or aneuploidy are not essential for MNTI tumorigenesis
in vivo. The differentiation of the MNTI cell line was to-
wards a melanotic appearance at initial early passage,
but ceased to produce melanin as it was propagated in
culture despite continued expression of HMB45. Our
findings contrast with those of Metwaly et al., who noted
that their derived MNT1/2/3 cell lines did not produce
melanin and were negative for HMB45 staining [24]. Partial
melanocytic differentiation can be induced by treating the
cells with endothelin-3 and vitamin D3, which restored
HMB45 expression, but not melanin production [24]. In
addition, we did not observe the structural aberrations re-
ported for these cell lines, for example, der(9)t(9;13)(p13;-
q12)add(9)(q34) and der(13;21)(q10;q10) were present in all
3 of the MNTI lines, and a der(19)t(11;19)(q13;p13) was
detected in 2 of the cell lines [24].
Our most notable observation was the detection of a
heterozygous, germline missense mutation in CDKN2A,
D74A, in this case which is predicted to be deleterious
by the Variant Effect Predictor (release 77, Ensembl).
Germline mutations in CDKN2A are responsible for fa-
milial melanoma syndromes, such as the intensively
studied p16-Leiden truncation mutation which causes
familial atypical multiple mole-melanoma susceptibility
[25]. Since CDKN2A mutations drive the proliferation of
melanocytes in familial melanoma and, as the large
melanin-expressing, epithelial-like cells in MNTI are,
most likely, immature melanocytes, we do not consider
the D74A to be simply a passenger mutation but infer a
role for it in contributing to tumor growth in this pa-
tient. Little is known concerning rates of LOH in familial
melanoma and whether this is necessary for the disease
phenotype. In one immunohistochemical study of p16
expression in 98 familial melanoma patients [26], a
single patient was found to be hemizygous for p16
suggesting that LOH, at least in early stage tumors, is
comparatively rare. Also, CDKN2A D74 mutations are in-
frequent and have never been described in melanoma, ei-
ther familial or sporadic, although a single report exists of
a somatic CDKN2A D74E mutation (COSM13768) in a
sporadic dysplastic nevus [27]. Regardless of its role in
tumorigenesis of the MNTI, it is probable that the germ-
line D74A CDKN2A mutation may also predispose pa-
tients to an increased risk of developing other cancers
later in life. Inferences may be drawn from the analyses of
cancer risk from previous large-scale studies. For individ-
uals carrying germline mutations in CDKN2A, the risk of
developing melanoma before the age of 80 has been esti-
mated to be 67 % [28]. In families carrying the p16-Leiden
mutation, the relative risk of developing cancers other
than melanoma is 4.4 [29] with a cumulative risk of devel-
oping pancreatic cancer before the age of 75 of 17 % [30].
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In terms of the functional effect of the variant in
CDKN2A (p16INK4A, D74A) on protein function, it is
likely that this variant is significant, as mutation of aspar-
tic acid 74, to asparagine has been identified in bladder
carcinoma [31] and esophageal squamous cell carcinoma
[32]. Mutation of D74 to alanine was subsequently de-
tected in a non-small cell lung carcinoma [33], with five
somatic, non-synonymous CDKN2A D74 mutations listed
in COSMIC for twelve samples: D74Y (COSM12509, lar-
ynx, lung, esophagus, gallbladder), D74N (COSM13474,
thyroid, esophagus), D74V (COSM13546, larynx, bile
duct), D74A (COSM4163712, thyroid) and D74E
(COSM13768, skin). Although D74A has not been studied
in vitro, a homologous mutation, D74N, was reported as
being one of four p16INK4A mutations which caused sig-
nificant disruption of the protein’s secondary structure,
assessed by circular dichroism spectroscopy, with the mis-
folding making the protein more susceptible to proteolysis
than wild-type p16 [34]. The functional consequences of
the D74N mutation were investigated by Yarbrough et al.
[35], who found that although the mutant protein bound
CDK4 and CDK6 with activity comparable to wild-type
p16, by affinity co-precipitation, it was defective in its abil-
ity to inhibit CDK6 kinase activity in an in vitro assay. In
addition, when ectopically expressed at low levels in
U2OS cells, the D74N mutant was unable to induce cell
cycle arrest in G1 [35]. The aspartic acid residue at pos-
ition 74 of p16 is evolutionarily conserved and occurs at
the C-terminal of the protein’s second ankyrin repeat [35].
We would predict that the loss of function in the p16
expressed from the mutant allele in our patient would be
more severe, as mutation of aspartic acid to asparagine is
a conservative substitution, whereas mutation of aspartic
acid to alanine involves loss of an acidic carboxyl side
chain and replacement of a hydrophilic residue with a
hydrophobic one. Despite identification of somatic D74A,
this mutation has not been previously observed in the
germline.
Although euploid, the genome of the MNTI appeared
highly unstable as evidenced by multiple chromosomal
rearrangements and fusion transcripts. We detected
three fusion genes with their reciprocals, which increases
our confidence that they are not false positives but are
most likely products of balanced chromosomal translo-
cations. The C19MC-RPLP1 fusion may be relevant as
fusions of C19MC with TTHY1 are found in embryonal
tumors with multilayered rosettes (ETMRs), where they are
believed to be responsible for the re-engagement of a neu-
rodevelopmental program that causes tumorigenesis [12].
Deregulation and amplification of C19MC by fusion with
TTHY1 is known to drive the expression of microRNAs
that suppress expression of retinoblastoma-like 2, RBL2.
Suppression of RBL2, in turn, prevents full methylation and
silencing of promoter 1B of a DNA methyltransferase,
DNMT3B, leading to the excessive transcription of its fetal
brain-specific isoform containing alternative exon 1B. It is
unlikely that exactly the same mechanism is active in the
MNTI, as we failed to detect either abnormally high
DNMT3B expression or suppression of RBL2 expres-
sion (data not shown). It is possible, however, that fu-
sion of RPLP1 to C19MC leads to the deregulation of
different, and potentially tumorigenic, microRNAs
within the cluster that have different targets. To test
this hypothesis, miRNA-Seq using a small RNA library
would be required to quantify the expression of mature
microRNA species from C19MC.
The functional consequences of the other reciprocal
fusions in the MNTI, RBBP4-TRA@ and H2AFV-RP11-
386 M24.4, are difficult to predict but both involve
epigenetic regulators. The protein product of RBBP4 is
retinoblastoma binding protein 4, a component of his-
tone deacetylase complexes, which has been implicated
in the transcriptional repression of E2F-responsive genes
via direct binding to Rb [36]. Fusion with TRA@, the T-
cell receptor alpha locus, implies a mechanism of over-
expression similar to the inappropriate activation of the
various transcription factor partner genes in T-precursor
Acute Lymphoblastic Leukemia (ALL). RBBP4, however,
has never been described as a partner gene in ALL and
we found its expression to be lower, rather than higher,
in the MNTI relative to the hNCC dataset. The H2AFV-
RP11-386 M24.4 fusion involves H2AFV (also known
as H2A.Z-2), which encodes a member of the H2A
family of histone proteins, and the pseudogene RP11-
386 M24.4. An in-frame, exonic breakpoint is in-
volved which would replace H2AFV coding sequences
with those from the pseudogene. Since there are H2A
transcript isoforms, however, and redundancy, this
loss of function may be compensated by another H2A
family member, such as H2A.Z-1. The reciprocal fu-
sion, RP11-386 M24.4-H2AFV, will not be translated
as RP11-386 M24.4 is a pseudogene. With respect to the
other fusions involving collagen genes, COL1A1 encodes
two α1 chains of type I collagen, the most abundant form
in healthy connective tissues. The α1 chains form a
heterotrimer with the α2 chain encoded by COL1A2 [37].
Expression of COL1A2 is frequently silenced by hyperme-
thylation of its promoter in colorectal cancer, cancer cell
lines [38] and in melanoma [37], suggesting a potential
role as a tumor suppressor. Type I collagen is the major fi-
brillary component of stroma in solid tumors and may be
produced either by the carcinoma cells themselves or by
stromal fibroblasts [38].
Since multiple lines of evidence point to MNTI having a
neural crest origin [1], it was of interest to profile gene ex-
pression in our patient’s tumor relative to untransformed
hNCC. We required a comparator to assess changes in
gene expression in our RNA-Seq data from baseline values.
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This was provided by an RNA-Seq dataset from an in vitro
model of human neural crest development [13]. The com-
parison yielded a signature of 185 genes with significantly
altered gene expression. As evidence of proof of concept,
we readily identified tyrosinase, TYR, as being highly
expressed in the MNTI, consistent with the excessive,
pathophysiological biosynthesis of melanin. We did not de-
tect strong expression of melanotransferrin (MFI2, CD228,
MAP97) mRNA, which has been reported for an MNTI
[39] or significantly elevated expression of MITF,
microphthalmia-associated transcription factor, the master
transcriptional regulator of melanogenesis. The gene most
highly expressed in hNCC and silent in the MNTI was
MIR4737. Of the putative hsa-miR-4737 targets, only EDN2
and MYOD1, were significantly upregulated in the MNTI.
Our GSEA results suggest that the pattern of expressed
genes in the MNTI has features in common with a dataset
for invasive ductal breast carcinoma [14]. LRRC15 (to single
out a gene from the leading edge set) encodes a leucine-
rich transmembrane protein which, in normal tissue, is only
expressed in the invasive cytotrophoblast layer of the pla-
centa [40]. Considering the small round cell component of
MNTI, it is noteworthy that LRRC15 was first identified as
being the transcriptional target of the EWSR1-WT1(+KTS)
fusion gene in desmoplastic small round cell tumor [40].
In summary, our data delineate a potentially complex,
multifactorial picture of the tumorigenic mechanisms
likely to be responsible for MNTI. Our main findings
are a germline mutation in CDKN2A, liable to pre-
dispose to tumor formation, that the tumor was euploid,
but expressed fusion genes caused by chromosomal
translocations, and that there were differences in the ex-
pression of a limited number of genes, relative to the
background of the neural crest, which may be key to the
tumor phenotype. The MNTI signature contains genes
associated with both melanocytic and myogenic differen-
tiation, as well as genes present in invasive ductal breast
carcinoma signatures. In the absence of CNV to account
for altered gene expression, epigenetic mechanisms are
implicated in the repression or de-repression of genes
that cause the deviation from the normal physiology of
the neural crest. The results of treating the MNTI cell
line with a panel of inhibitors of epigenetic regulators
are consistent with this and point to the involvement of
altered methylation of histone lysines in maintenance of
the disease phenotype. In addition, the fusion of RPLP1
with C19MC suggests a microRNA-mediated epigenetic
effect may be present which is analogous to, but not
identical with, that caused by a TTHY1-C19MC fusion.
Methods
Tumor processing
A tumor measuring 5 × 2.5 × 2.5 cm was excised en bloc
from the patient’s fibula. The tumor was snap frozen in
liquid nitrogen and stored at −80 °C. Informed consent
was obtained from the patient’s parents for the use of
the tumor in research, in accordance with the ethics of
the Oxford University Hospitals NHS Trust (REC C 09/
H0606/11) and under the terms of the Human Tissue
Act (HTA License 12217).
RNA and DNA extraction, quality control and library
preparation
Total RNA was extracted using an RNeasy Fibrous Tissue
kit (Qiagen, Manchester, UK) from a 12.5 mg piece of the
tumor, homogenized with a hand-held TissueRuptor
homogenizer (Qiagen). Genomic DNA was extracted
using a DNeasy Blood and Tissue kit (Qiagen) from a
19.1 mg piece of the tumor, homogenized with a TissueR-
uptor and digested overnight with proteinase K (Qiagen).
Genomic DNA extracted from the patient’s blood was ob-
tained from the Children’s Cancer and Leukaemia Group
Biobank, Newcastle. For whole-exome sequencing, targets
were captured using SureSelect (Agilent, Stockport, UK).
Samples were prepared and enriched according to the
manufacturer’s instructions. The concentration of
each library was determined using a QPCR NGS Li-
brary Quantification Kit (G4880A, Agilent). Samples
were pooled prior to sequencing with each sample at
a final concentration of 10 nM.
SNP arrayCGH, whole-exome sequencing and RNA-Seq
Aliquots of genomic DNA from the tumor and blood
were hybridized to a Cytosure Cancer + small nucleotide
polymorphism (SNP) array (Oxford Gene Technology,
Begbroke, UK) and read on a SureScan scanner (Agilent).
The array was a 4 × 180 k design, comprising a whole gen-
ome backbone with a greater density of probes for 1500
cancer-associated genes. Whole-exome sequencing was
done on a MiSeq using TruSeq version 3 chemistry to
generate 2 × 150 base reads (Illumina, Chesterford, UK).
Paired-end RNA-Seq reads were acquired on a HiSeq
2500 (Illumina).
Genomic and transcriptomic analysis
ArrayCGH data were analyzed using CytoSure Interpret
software, version 4.3.2 (Oxford Gene Technology). For
whole-exome sequencing, reads from Fastq files were
mapped to the reference human genome (hg19/b37)
with the Burrows-Wheeler Aligner (BWA) package, ver-
sion 0.6.2. Local realignment of the mapped reads
around potential insertion/deletion (indel) sites was car-
ried out with the Genome Analysis Tool Kit, version 1.6
(GATK, Broad Institute). Duplicate reads were marked
using Picard, version 1.89 (Broad Institute). Additional
BAM file manipulations were performed with Samtools
0.1.18. Base quality scores were recalibrated using GATK’s
covariance recalibration. SNP variants were called using
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VarScan2 and Indel variants were called using GATK
SomaticIndelDetector. SNP novelty was determined
against dbSNP release 135. Deleterious SNPs were identi-
fied using the Variant Effect Predictor, release 77
(Ensembl). Putative fusion genes were identified from
RNA-Seq data using FusionCatcher, version 0.99.4c [11].
For analysis of transcript abundance from RNA-Seq data,
analyses were carried out using the software tools in the
Tuxedo pipeline [41]. Paired-end reads from Fastq files
were aligned to the human genome (hg19/b37) with the
TopHat-Bowtie2 aligner, versions 2.0.13 and 2.2.5, respect-
ively, and expression of transcripts was quantified with
Cufflinks, version 2.2.1, as fragments per kilobase per mil-
lion mapped reads (FPKM). For statistical analysis of dif-
ferential expression in RNA-Seq data, the getSig function
of CummeRbund was used, with the default alpha of 0.05,
to access genes with significantly different expression ac-
cording to adjusted P-values calculated by Cufflinks [42].
Derivation of MNTI cell line
A section of tumor approximately 0.5 cm3 was cut from
the surgical resection specimen and was homgenized by
hand prior to overnight digestion with Dispase II (Roche,
Burgess Hill, UK). Cells were cultured in alpha MEM
(Lonza, Slough, UK) with 20 % heat inactivated fetal calf
serum, 4 mM glutamine, 100 units/mL penicillin and
100 μg/mL streptomycin in a humidified incubator at
37 °C and 5 % CO2. After approximately 2 weeks with
no visible proliferation, the cell number began to in-
crease. Cells were passaged at a ratio of 1:5 when they
reached 80 % confluence using trypsin-EDTA (Sigma,
Poole, UK). Immunohistochemical analysis of the cells at
passage 6 was performed to characterize the identity of
the proliferating cells.
Screen of small molecule inhibitors of epigenetic
regulators for compounds that reduce the viability of the
MNTI cell line
Cells in the exponential growth phase were seeded in
96-well plates at a density of 3000 cells per well in a final
volume of 100 μL and were treated, in quadruplet, with
a single dose of 47 small molecule inhibitors targeted
against proteins involved in epigenetic processes. Viabil-
ity was measured at days 3, 7 and 10 using PrestoBlue
(Life Technologies) according to the manufacturer’s
protocol and normalized to vehicle controls. Day 3 via-
bility was determined from triplicate readings and viabil-
ity on days 7 and 10 from duplicate readings.
Assay of sensitivity of cell lines to the specific Cdk4/Cdk6
inhibitor palbociclib
Cells were seeded in 96-well plates at a density of 2000
cells per well and were treated with doses of palbociclib
(Cambridge Bioscience, Cambridge, UK) in the range of
0.1 to 30 μM. After 72 h, viable cells were assayed by
adding CellTiter 96 AQueous One Solution Cell Prolif-
eration MTS reagent (Promega, Southampton, UK) and
measuring the absorbance of the formazan product at
490 nm. Log dose–response curves were obtained by fit-
ting a four-parameter logistic function to the data (R
3.3.2, R Foundation for Statistical Computing). Mean
IC50 values were derived from at least three independent
experiments.
Additional file
Additional file 1: Final list of candidate fusion genes with genomic
coordinates and sequences output from FusionCatcher. (CSV 105 kb)
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